

## CONTENTS

<b>Acknowledgments</b> .....	4
<b>Methodology</b> .....	6
Data Validation Process.....	6
<b>Market Characteristics</b> .....	7
Specialty Manufacturers.....	8
Specialty Distributors.....	8
Products in Development.....	9
Specialty Brands and Generics.....	9
Formulation and Packaging.....	10
Customer Groups.....	10
Product Contracting via GPOs.....	11
Pharmaceutical Administration Setting.....	12
Risk Evaluation and Mitigation Strategy (REMS).....	13
<b>Finance</b> .....	14
Specialty Distributor Gross Sales.....	14
Chargebacks.....	14
<b>Operations &amp; Handling</b> .....	16
Operations and Handling Requirements.....	16
Warehousing and Storage.....	18
Order Management and Fill Rates.....	21
Shipping Requirements.....	21
Specialty Manufacturers.....	22
Specialty Distributors.....	23
In-Transit Insurance.....	25
Specialty Manufacturers Services.....	27
Value-Added Services.....	28
Specialty Distributors Services.....	28
<b>Transportation &amp; Delivery</b> .....	31
Getting Product to Market.....	31
Transportation Carriers.....	31
Product Delivery.....	33
Frequency of Delivery.....	34
Emergency Capabilities.....	35

<b>Returns</b> .....	36
<b>Information Technology</b> .....	39
Specialty Manufacturers.....	39
Specialty Distributors.....	40
2D Barcodes or RFID in Use.....	41
Specialty Manufacturers.....	41
Specialty Distributors.....	41
Barriers to Item Level Serialization.....	42
<b>Data</b> .....	43
<b>Oncology</b> .....	45
Oncology Segment Characteristics.....	46
New Technologies on the Horizon.....	48
Changing Payment Options.....	48
<b>Specialty Pharmaceuticals Insurance Coverage</b> .....	49
Medical and Pharmacy Benefit Coverage.....	49
Products Covered Under Both Medical and Pharmacy Benefits (Percentage of Lives): 2008.....	50
The Medical Benefit: Average Sales Price (ASP)-Based Reimbursement from CMS.....	50
The Pharmacy Benefit.....	50
Patient Assistance Program.....	52
<b>Biosimilars</b> .....	53
Projected Cost Savings to the U.S. Healthcare System.....	54
Legislation in Review.....	55
Pricing Implications of Biosimilars.....	56
<b>Appendix A: FDA Approved Risk Evaluation and Mitigation Strategies (REMS)</b> .....	57
<b>Appendix B: Products Deemed to Have Risk Evaluation and Mitigation Strategies for Purposes of the Food and Drug Administration Amendments Act of 2007</b> .....	60
<b>Appendix C: FDA Approvals and Expanded Indications for Selected Specialty Drugs from June 2006 through August 2008</b> .....	61